Chemify Announces £36m Funding to Digitise Chemistry

Chemify, a pioneering company operating its proprietary molecular design, discovery, and chemical manufacturing technology to provide pharmaceutical, biotechnology, and industrial partners with better molecules, has announced funding of £36 million.

Series A funding is led by Triatomic Capital, joined by new investors including Hong-Kong based Horizon Ventures, US-based Rocketship Ventures, Possible Ventures, Alix Ventures, Scotland-based Eos, and the UK Government Innovation Accelerator program. Existing investor BlueYard Capital also participated in the round.
 
Founded in 2019 by CEO Lee Cronin with backing from David Cleevely (co-founder of Abcam), Chemify is based on decades of chemistry research, robotics, AI, and conceptual advancements from Cronin’s Digital Chemistry Laboratory at the University of Glasgow (from which it spun-out in March 2022).

Professor Cronin’s pioneering research spans the digitisation of chemistry including the use of artificial intelligence in chemistry to explore chemical space - the trillions of possible combinations of natural elements.

Chemify can help reduce the amount of costly and time-consuming experimentation required to discover promising new molecules, speeding up their development as products to underpin advances in medicine, farming, materials science, and green energy.

With over £25 million invested in the foundational research behind Chemify, the team developed a new digital chemical approach to program chemistry.
 
Chemify’s vision is to build the infrastructure to digitise chemistry and enable the execution of chemical code for drug discovery, chemical synthesis, and materials discovery. Chemify is creating a digital chemical future where the access to important molecules, drugs, and new materials, currently unimaginable, are instantly accessible.

Chemify’s platform technology has been proven to have broad and transformative applications including:

• Synthesis of complex molecules for partners increasing speed, yield and efficiency.
• Drug discovery using integrated code to molecules system producing novel libraries.
• Design of new materials with desired electronic properties for application in high value devices and catalysts.

By working closely with select partners with world-class expertise in drug discovery, advanced materials, industrial chemicals, and other specialties, Chemify aims to provide access to its platform and help solve the most complex and impactful chemical design and manufacturing challenges.

Source: University of Glasgow